PT-141 (Bremelanotide)
medicationVyleesi
Melanocortin agonist (sexual health)
Research status · FDA-approved (specific use)
FDA-approved as Vyleesi for one specific use: generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Any other use is off-label and not FDA-approved. Prescription only.
Bremelanotide is a melanocortin-receptor agonist approved for a specific sexual-desire condition in premenopausal women and discussed more broadly for libido. Broader use is off-label and a clinician-level decision; unregulated products carry identity and purity risks.
How it works
Activates central melanocortin receptors (notably MC4R) involved in sexual-desire pathways, rather than acting on blood flow the way ED medications do.
Commonly discussed use cases
- HSDD in premenopausal women (approved)
- Libido (off-label, discussed)
Supposed / potential benefits
- Improved sexual-desire and reduced-distress measures in its approved population
Common side effects
- Nausea
- Flushing
- Headache
- Injection-site reactions
- Temporary blood-pressure increase
Warnings & contraindications
- Not for people with uncontrolled high blood pressure or known cardiovascular disease
- Repeated use can cause focal darkening of skin/gums (hyperpigmentation)
- Off-label sourcing is unregulated — identity and purity are not guaranteed
Typical timing considerations
Approved regimen is an as-needed subcutaneous injection ahead of anticipated activity; follow the prescribing information.
Administration route
Subcutaneous injection
Storage
Per product label; follow pharmacy instructions.
Questions to ask your clinician
- Is this appropriate and on-label for me?
- Any blood-pressure or cardiovascular reason to avoid it?
- What side effects should prompt me to stop?
Commonly tracked in Reta
Tracking fields organize user-entered, clinician-directed routines — Reta never recommends or computes doses.
Track this in Reta
Beta members get a ready-made tracker for PT-141 (Bremelanotide) — schedule, dose log, injection-site rotation, reminders, and check-ins — for organizing a clinician-directed routine. Personal tracking is available to everyone during the Public Beta.
Reta is a tracking and education tool — not a medical provider. Nothing here is a diagnosis, treatment, prescription, or dosing recommendation. Peptides and medications should only be used under the direction of a licensed clinician. Talk to a qualified clinician before starting, stopping, combining, or changing anything. Many compounds below are not FDA-approved for human use; some are investigational or sold through unregulated channels where purity and dosing are not guaranteed.